Role of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome in occurrence of coronary heart disease in patients with type 2 diabetes mellitus
- Journal of Third Military Medical University Vol. 39, Issue 8, Pages: 801-806(2017)
- 作者机构：
- 作者简介：
- 基金信息：the General Program of Medical Scientific Research From Chongqing Health and Family Planning Commission(2015XMSB000312)
DOI：10.16016/j.1000-5404.201611179
CLC：-
Published：2017-04
- 稿件说明：
移动端阅览
Yunlan Cao, Longjiang Hu, Yaoming Song. Role of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome in occurrence of coronary heart disease in patients with type 2 diabetes mellitus[J]. Journal of Third Military Medical University, 2017, 39(8): 801-806.
Yunlan Cao, Longjiang Hu, Yaoming Song. Role of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome in occurrence of coronary heart disease in patients with type 2 diabetes mellitus[J]. Journal of Third Military Medical University, 2017, 39(8): 801-806. DOI： 10.16016/j.1000-5404.201611179.
摘要
Abstract
Objective
2
To investigate the role of inflammasome of nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3) in the occurrence of coronary heart disease (CHD) in patients with type 2 diabetes mellitus (T2DM).
Methods
2
One hundred and thirty patients hospitalized in the Department of Cardiology
Xinqiao Hospital between March and August 2016 were enrolled in this study
including 40 with CHD
20 with T2DM group
and 40 with T2DM complicated by CHD
with 30 individuals without T2DM or CHD serving as the control group. Peripheral blood monocytes (HPBMCs) and plasma were collected from the subjects to detect the transcription and protein levels of NLRP3
apoptosis-associated speck-like protein (ASC) and caspase-1 using real-time qPCR and Western blotting; the plasma level of IL-1β was detected with enzyme-linked immunosorbent assay (ELISA).
Results
2
Both the mRNA and protein levels of NLRP3
ASC and caspase-1 in the HPBMCs were significantly increased in patients with CHD
T2DM and T2DM complicated by CHD groups as compared with the control group (
P
<
0.05). HPBMCs from diabetic patients with CHD patien
ts showed significantly higher ASC and caspase-1 mRNA levels and NLRP3 protein level than those from CHD or T2DM patients (
P
<
0.05). The mean plasma levels of IL-1β were 24.05±1.00
22.86±1.66
and 26.85±1.45 ng/L in CHD
T2DM and T2DM complicated by CHD groups
respectively
all significantly higher than the level in the control group (12.53±2.79 ng/L
P
<
0.05).
Conclusion
2
The aberrant activation of NLRP3 inflammasome promotes the occurrence of CHD in patients with T2DM and may serve as a new target for prevention and treatment of the CHD in diabetic patients.
关键词
Keywords
references
Grant R W Dixit V D Mechanisms of disease: inflammasome activation and the development of type 2 diabetes Front Immunol 2013 4 50 10.3389/fimmu.2013.00050 Grant R W, Dixit V D. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes[J]. Front Immunol, 2013. 4: 50. DOI:10.3389/fimmu.2013.00050.
Meylan E Tschopp J Karin M Intracellular pattern recognition receptors in the host response Nature 2006 442 7098 39 44 10.1038/nature04946 Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response[J]. Nature, 2006, 442(7098): 39-44. DOI:10.1038/nature04946.
Binder C J Chang M K Shaw P X Innate and acquired immunity in atherogenesis Nat Med 2002 8 11 1218 1226 10.1038/nm1102-1218 Binder C J, Chang M K, Shaw P X, et al. Innate and acquired immunity in atherogenesis[J]. Nat Med, 2002, 8(11): 1218-1226. DOI:10.1038/nm1102-1218.
Hansson G K Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 2005 352 16 1685 1695 10.1056/NEJMra043430 Hansson G K. Inflammation, atherosclerosis, and coronary artery disease[J]. N Engl J Med, 2005, 352(16): 1685-1695. DOI:10.1056/NEJMra043430.
Wen H Ting J P O'Neill L A A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation Nat Immunol 2012 13 4 352 357 10.1038/ni.2228 Wen H, Ting J P, O'Neill L A. A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation[J]. Nat Immunol, 2012, 13(4): 352-357. DOI:10.1038/ni.2228.
Duewell P Kono H Rayner K J NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature 2010 464 7293 1357 1361 10.1038/nature08938 Duewell P, Kono H, Rayner K J, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals[J]. Nature, 2010, 464(7293): 1357-1361. DOI:10.1038/nature08938.
Sun C Fan S Wang X Purple sweet potato color inhibits endothelial premature senescence by blocking the NLRP3 inflammasome J Nutr Biochem 2015 26 10 1029 1040 10.1016/j.jnutbio.2015.04.012 Sun C, Fan S, Wang X, et al. Purple sweet potato color inhibits endothelial premature senescence by blocking the NLRP3 inflammasome[J]. J Nutr Biochem, 2015, 26(10): 1029-1040. DOI:10.1016/j.jnutbio.2015.04.012.
Lee H M Kim J J Kim H J Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes Diabetes 2013 62 1 194 204 10.2337/db12-0420 Lee H M, Kim J J, Kim H J, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes[J]. Diabetes, 2013, 62(1): 194-204. DOI:10.2337/db12-0420.
Hayden J M Reaven P D Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors Curr Opin Lipidol 2000 11 5 519 528 10.1097/00041433-200010000-00010 Hayden J M, Reaven P D. Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors[J]. Curr Opin Lipidol, 2000, 11(5): 519-528. DOI:10.1097/00041433-200010000-00010.
Pant S Deshmukh A Gurumurthy G S Inflammation and atherosclerosis—revisited J Cardiovasc Pharmacol Ther 2014 19 2 170 178 10.1177/1074248413504994 Pant S, Deshmukh A, Gurumurthy G S, et al. Inflammation and atherosclerosis—revisited[J]. J Cardiovasc Pharmacol Ther, 2014, 19(2): 170-178. DOI:10.1177/107424841 3504994.
Lu X Kakkar V Inflammasome and atherogenesis Curr Pharm Des 2014 20 1 108 124 10.2174/13816128113199990586 Lu X, Kakkar V. Inflammasome and atherogenesis[J]. Curr Pharm Des, 2014, 20(1): 108-124.
He Y Zeng M Y Yang D NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux Nature 2016 530 7590 354 357 10.1038/nature16959 He Y, Zeng M Y, Yang D, et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux[J]. Nature, 2016, 530(7590): 354-357. DOI:10.1038/nature16959.
Satoh M Tabuchi T Itoh T NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin Clin Sci 2014 126 3 233 241 10.1042/CS20130043 Satoh M, Tabuchi T, Itoh T, et al. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin[J]. Clin Sci, 2014, 126(3): 233-241. DOI:10.1042/CS20130043.
Dowling J K O'Neill L A Biochemical regulation of the inflammasome Crit Rev Biochem Mol Biol 2012 47 5 424 443 10.3109/10409238.2012.694844 Dowling J K, O'Neill L A. Biochemical regulation of the inflammasome[J]. Crit Rev Biochem Mol Biol, 2012, 47(5): 424-443. DOI:10.3109/10409238.2012.694844.
Haneklaus M O'Neill L A Coll R C Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments Curr Opin Immunol 2013 25 1 40 45 10.1016/j.coi.2012.12.004 Haneklaus M, O'Neill L A, Coll R C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments[J]. Curr Opin Immunol, 2013, 25(1): 40-45. DOI:10.1016/j.coi.2012.12.004.
Bauernfeind F G Horvath G Stutz A Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression J Immunol 2009 183 2 787 791 10.4049/jimmunol.0901363 Bauernfeind F G, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression[J]. J Immunol, 2009, 183(2): 787-791. DOI:10.4049/ jimmunol.0901363.
Sergin I Bhattacharya S Emanuel R Inclusion bodies enriched for p62 and polyubiquitinated proteins in macrophages protect against atherosclerosis Sci Signal 2016 9 409 ra2 10.1126/scisignal.aad5614 Sergin I, Bhattacharya S, Emanuel R, et al. Inclusion bodies enriched for p62 and polyubiquitinated proteins in macrophages protect against atherosclerosis[J]. Sci Signal, 2016, 9(409): ra2. DOI:10.1126/scisignal.aad5614.
0
Views
0
下载量
0
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
